Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013) /
Advances in CLL from iwCLL 2013

9th - 11th Sep 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.13
Views: 6635
Rating:

Prof Michael Hallek, Prof Susan O’Brien, Prof Jan Burger, Prof Anders Österberg

Chaired by Professor Michael Hallek, University of Cologne, Germany, this expert panel discussion at the iwCLL 2013 meeting in Cologne, Germany, includes the following experts:

-Professor Susan O’Brien, MD Anderson Cancer Center, Houston, Texas, USA
-Dr Kanti Rai, Long Island Jewish Medical Center, New York, USA
-Professor Jan Burger, MD Anderson Cancer Centre, Houston, Texas, USA,
-Professor Anders Österberg, Karolinska Hospital, Stockholm, Sweden

The experts share their highlights from this comprehensive meeting.  Topics discussed include the value of chemoimmunotherapy.  The experts outline the need to identify low- vs. high-risk patients, latest results and on-going studies in this area with novel therapies, eg, BCR inhibitors.  They also comment on the continuing role of older agents, eg, chlorambucil in combination, in appropriate patients, eg, in slow go or no go patients.  There is an interesting conversation on the implications of minimal residual disease (MRD)-negativity observed with the chlorambucil/obinutuzumab combination. 

Moving on to comment on the exciting era of novel therapies in CLL that we are now entering, the group share their views on latest results with novel agents, such as the Bruton's tyrosine kinase (BTK) inhibitor – ibrutinib, and the PI3K delta inhibitor - GS-1101, which are both targeting signalling pathways important in the biology of the disease.  The report of BTK mutations presented at the iwCLL 2013 meeting is also discussed.  The group share their excitement at the wealth of new agents being investigated and point to CLL becoming a chronic disease in the future because of these novel agents.  However, with the increasing number of new agents expected in CLL over the next few years, comments are also made on the cost of new therapies and the implications of this to cost-conscious physicians.

The experts also comment on how and when to proceed with allogeneic stem cell transplantation with the novel agents.  They discuss issues surrounding when transplantation could be delayed and how this might change in the future.

Finally, the experts each outline their personal highlights from the 15th iwCLL 2013 meeting, and re-emphasise their excitement in the advances being made in the treatment of CLL.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation